Copenhagen, Denmark; February 28, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 385,087 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
450 shares at DKK 31.75,
2,750 shares at DKK 40.41,
750 shares at DKK 45.24,
3,750 shares at DKK 46.74,
300 shares at DKK 66.60,
375 shares at DKK 67.50,
4,250 shares at DKK 68.65,
1,250 shares at DKK 79.25,
25,000 shares at DKK 80.55,
187 shares at DKK 98,
16,110 shares at DKK 129.75,
8,500 shares at DKK 174,
1,844 shares at DKK 210,
8,200 shares at DKK 220.40,
575 shares at DKK 225.30,
40,115 shares at DKK 225.90,
3,425 shares at DKK 231.50,
350 shares at DKK 234,
400 shares at DKK 234.75,
41,000 shares at DKK 246,
67,490 shares at DKK 254,
35,050 shares at DKK 272,
8,550 shares at DKK 326.50,
125 shares at DKK 329,
14,299 shares at DKK 337.40,
50,228 shares at DKK 352.50,
40,250 shares at DKK 364,
500 shares at DKK 466.20,
175 shares at DKK 623.50,
2,875 shares at DKK 636.50 and
5,964 shares at DKK 939.50.
Proceeds to the company are approximately DKK 103.3 million. The increase corresponds to approx. 0.6 % of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.